SGLT2 Inhibitors: A New Class of Diabetes Medications
Ueda2015 canagliflozin dr.inass shaltout
Mode of action of SGLT2 inhibitors in the kidney. Copied with... | Download Scientific Diagram
Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways | Scientific Reports
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation - American Journal of Kidney Diseases
ERA-EDTA on Twitter: "Mechanism of action #canagliflozin #eraedta19… "
Update on Mx of T 2 DM Emerging
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus - ScienceDirect
Swiss Medical Weekly - Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure | SpringerLink
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure | Heart
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin Singh SK, Gupta A K - Muller J Med Sci Res
Mechanism of action of canagliflozin on SGLT-2 in the renal proximal... | Download Scientific Diagram
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research | Diabetes
Canagliflozin review – safety and efficacy profile in patients w | DMSO
SGLT2 inhibitors
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus | Cardiovascular Diabetology | Full Text
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors - Brown - 2019 - Diabetes, Obesity and Metabolism - Wiley Online Library
Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes | Clinical Diabetes
SGLT 2 inhibitors
SGLT-2 inhibitors in diabetes: a focus on renoprotection
